Literature DB >> 33901107

Clinical Utility of SPECT in the Heart Transplant Population: Analysis From a Single Large-volume Center.

Jack Aguilar1,2, Robert J H Miller1,3, Yuka Otaki1, Balaji Tamarappoo1, Sean Hayes1, John Friedman1, Piotr J Slomka1, Louise E J Thomson1, Michelle Kittleson2, Jignesh K Patel2, Jon A Kobashigawa2, Daniel S Berman1.   

Abstract

BACKGROUND: Survival after heart transplant has greatly improved, with median survival now over 12 years. Cardiac allograft vasculopathy (CAV) has become a major source of long-term morbidity and mortality. Single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) is used for CAV surveillance, but there is limited data on its prognostic utility.
METHODS: We retrospectively identified patients undergoing SPECT MPI for CAV surveillance at a single, large-volume center. Images were assessed with semiquantitative visual scoring (summed stress score [SSS] and summed rest score) and quantitatively with total perfusion defect (TPD).
RESULTS: We studied 503 patients (mean age 62.5, 69.3% male) at a median of 9.0 years post-transplant. During mean follow-up of 5.1 ± 2.5 years, 114 (22.6%) patients died. The diagnostic accuracy for significant CAV (ISHLT grade 2 or 3) was highest for SSS with an area under the curve of 0.650 and stress TPD (area under the curve, 0.648), with no significant difference between SSS and stress TPD (P = 0.061). Stress TPD (adjusted hazard ratio, 1.07; P = 0.018) was independently associated with all-cause mortality, while SSS was not (P = 0.064). The prognostic accuracy of quantitative assessment of perfusion tended to be higher compared with semiquantitative assessment, with the highest accuracy for stress TPD (area under the receiver operating curve 0.584).
CONCLUSIONS: While SPECT MPI identified a cohort of higher risk patients, with quantitative analysis of perfusion demonstrating higher prognostic accuracy. However, the overall prognostic accuracy was modest and alternative noninvasive modalities may be more suitable for CAV surveillance.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 33901107      PMCID: PMC8528902          DOI: 10.1097/TP.0000000000003791

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   5.385


  42 in total

1.  Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials.

Authors:  Omar Wever-Pinzon; Jorge Romero; Iosif Kelesidis; James Wever-Pinzon; Carlos Manrique; Deborah Budge; Stavros G Drakos; Ileana L Piña; Abdallah G Kfoury; Mario J Garcia; Josef Stehlik
Journal:  J Am Coll Cardiol       Date:  2014-03-26       Impact factor: 24.094

2.  International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010.

Authors:  Mandeep R Mehra; Maria G Crespo-Leiro; Anne Dipchand; Stephan M Ensminger; Nicola E Hiemann; Jon A Kobashigawa; Joren Madsen; Jayan Parameshwar; Randall C Starling; Patricia A Uber
Journal:  J Heart Lung Transplant       Date:  2010-07       Impact factor: 10.247

3.  PET Assessment of Epicardial Intimal Disease and Microvascular Dysfunction in Cardiac Allograft Vasculopathy.

Authors:  Sharon Chih; Aun Yeong Chong; Fernanda Erthal; Robert A deKemp; Ross A Davies; Ellamae Stadnick; Derek Y So; Christopher Overgaard; George Wells; Lisa M Mielniczuk; Rob S B Beanlands
Journal:  J Am Coll Cardiol       Date:  2018-04-03       Impact factor: 24.094

4.  Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy.

Authors:  Paco E Bravo; Brian A Bergmark; Tomas Vita; Viviany R Taqueti; Ankur Gupta; Sara Seidelmann; Thomas E Christensen; Michael T Osborne; Nishant R Shah; Nina Ghosh; Jon Hainer; Courtney F Bibbo; Meagan Harrington; Fred Costantino; Mandeep R Mehra; Sharmila Dorbala; Ron Blankstein; Akshay Desai; Lynne Stevenson; Michael M Givertz; Marcelo F Di Carli
Journal:  Eur Heart J       Date:  2018-01-21       Impact factor: 29.983

5.  Noninvasive Detection of Cardiac Allograft Vasculopathy by Stress Exercise Echocardiographic Assessment of Myocardial Deformation.

Authors:  Tor Skibsted Clemmensen; Hans Eiskjær; Brian Bridal Løgstrup; Lars Poulsen Tolbod; Hendrik J Harms; Kirsten Bouchelouche; Camilla Hoff; Jørgen Frøkiær; Steen Hvitfeldt Poulsen
Journal:  J Am Soc Echocardiogr       Date:  2016-02-18       Impact factor: 5.251

6.  Myocardial perfusion imaging with PET.

Authors:  Ryo Nakazato; Daniel S Berman; Erick Alexanderson; Piotr Slomka
Journal:  Imaging Med       Date:  2013-02-01

7.  Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single-photon emission computed tomography: a clinical validation study.

Authors:  D S Berman; H Kiat; J D Friedman; F P Wang; K van Train; L Matzer; J Maddahi; G Germano
Journal:  J Am Coll Cardiol       Date:  1993-11-01       Impact factor: 24.094

8.  Coronary computed tomography-angiography quantitative plaque analysis improves detection of early cardiac allograft vasculopathy: A pilot study.

Authors:  Robert J H Miller; Jacek Kwiecinski; Kevin S Shah; Evann Eisenberg; Jignesh Patel; Jon A Kobashigawa; Babak Azarbal; Balaji Tamarappoo; Daniel S Berman; Piotr J Slomka; Evan Kransdorf; Damini Dey
Journal:  Am J Transplant       Date:  2019-12-21       Impact factor: 8.086

9.  Dobutamine stress echocardiography is inadequate to detect early cardiac allograft vasculopathy.

Authors:  Kevin J Clerkin; Maryjane A Farr; Susan W Restaino; Ziad A Ali; Donna M Mancini
Journal:  J Heart Lung Transplant       Date:  2016-05-21       Impact factor: 10.247

10.  Comparative Prognostic and Diagnostic Value of Myocardial Blood Flow and Myocardial Flow Reserve After Cardiac Transplantation.

Authors:  Robert J H Miller; Osamu Manabe; Balaji Tamarappoo; Sean Hayes; John D Friedman; Piotr J Slomka; Jignesh Patel; Jon A Kobashigawa; Daniel S Berman
Journal:  J Nucl Med       Date:  2019-08-26       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.